CureVac NV earnings missed by €0.21, revenue fell short of estimates

Investing.com - CureVac NV (NASDAQ: CVAC) reported second quarter EPS of €-0.260, €0.21 worse than the analyst estimate of €-0.046. Revenue for the quarter came in at €1.25M versus the consensus estimate of €34.59M.

CureVac NV’s stock price closed at €5.45. It is up 31.010% in the last 3 months and up 68.730% in the last 12 months.

CureVac NV saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See CureVac NV’s stock price’s past reactions to earnings here.

According to InvestingPro, CureVac NV’s Financial Health score is "excellent performance".

Check out CureVac NV’s recent earnings performance, and CureVac NV’s financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar